News

April 6, 2022
Oncolytics Biotech® Letter to Shareholders – Update on Recent Progress
March 31, 2022
Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
March 24, 2022
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort
March 17, 2022
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep’s Stimulation of Natural Killer Cell Anti-Cancer Activity
March 9, 2022
Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting
March 9, 2022
Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting
March 3, 2022
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
February 22, 2022
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
February 2, 2022
Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
January 27, 2022
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up